Bispecific T-cell engaging antibodies for cancer therapy
about
Bispecific antibodies for cancer therapy: the light at the end of the tunnel?The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemiaEngineered IgG1-Fc--one fragment to bind them allAnti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma TherapyRecent advances in the field of anti-cancer immunotherapyEvaluation of current cancer immunotherapy: hemato-oncologyCD19 as an attractive target for antibody-based therapyNew antibody approaches to lymphoma therapyOne-step enzymatic modification of the cell surface redirects cellular cytotoxicity and parasite tropism.Bispecific T-cell engagers for cancer immunotherapy.The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and RiskThe CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEARetargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR".T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.Solid-phase bioconjugation of heterobifunctional adaptors for versatile assembly of bispecific targeting ligands.Cancer therapy with bispecific antibodies: Clinical experience.Bispecific antibodies engage T cells for antitumor immunotherapy.O-glycosylation of glycine-serine linkers in recombinant Fc-fusion proteins: attachment of glycosaminoglycans and other intermediates with phosphorylation at the xylose sugar subunit.Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemiasMacrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodiesTargeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.Protein conjugation with genetically encoded unnatural amino acids.Synthesis of bispecific antibodies using genetically encoded unnatural amino acids.The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity.Characterization of a novel single-chain bispecific antibody for retargeting of T cells to tumor cells via the TCR co-receptor CD8Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cellsTreatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.Engager T cells: a new class of antigen-specific T cells that redirect bystander T cellsB7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor ImmunityImmunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma.A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties.Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia.Large-Scale Purification of r28M: A Bispecific scFv Antibody Targeting Human Melanoma Produced in Transgenic Cattle.A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy.Immunotherapy targets in pediatric cancer.T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.In-silico discovery of cancer-specific peptide-HLA complexes for targeted therapyAntibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme ActivityRedirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.
P2860
Q24644083-4CF7F507-60E7-475F-9BD8-B5E479A657CAQ26744280-9B35826B-1D6B-4004-BC8C-8EBB40E6AB8AQ26766715-2D6E4916-4ECC-475F-BA0F-4FC4E1E63F99Q26775363-767CC2A2-1DAE-40E9-AFDB-9F0CB15C163CQ26775602-82A6E248-5C2E-4055-ABD1-62922FC3F8AAQ27006179-27925964-0953-4507-8AFF-A0D5633EFE45Q27011836-374969B3-FB16-44F6-9C66-4AA97FD7BA8EQ27022373-B24A3AF0-B070-4868-A51A-D2E8B7AB6860Q27339549-8D772D5C-2EC4-4159-B08D-D6E7CE1E5146Q27693313-E717A90F-F40E-455E-BC4E-CEB05295B39FQ28547458-F31D6B32-E9FD-4AA1-8EFD-39A01EE359E9Q28730117-EACB3D21-9BD0-457C-928D-39BE1312CA5EQ33761755-4F25ABAE-0CEF-4EE4-86BD-43FD73A29F75Q34005156-F82D7C4E-C340-47B0-8480-56DB3D6818A5Q34074743-CEAE5153-3813-4611-8736-DD1C4985F49CQ34118856-43A0B1CB-22AF-4D44-9A1E-0F3A88DD841AQ34174334-B824D5A3-4DBA-4739-B393-422F8B7B623CQ34223974-89D476E6-7C2E-41B5-B619-04A4B6286A8CQ34369841-487A2BE2-4F09-483D-936C-9661EEAAA339Q34598149-7B0D22A4-F743-47CC-809B-68BAE09133F2Q34748489-67161181-763B-4753-9BE5-5A32AE3E7A0FQ34838057-F7C03CE8-D954-4D82-B049-6046CDE1F901Q34986422-C80E63EB-CFD0-44B0-9DB5-2E865A20E4BBQ35032671-DB9500C3-DA30-403A-8F2A-B6202DE05F4BQ35153908-E20271FE-C24D-4129-855D-F310FABCCCC3Q35368001-68EACEF2-B633-4B0E-9F2C-05EAD9F3E1A0Q35446333-50623F48-5D06-4667-9798-2F00B0EF5278Q35591391-60F7CFA5-80D1-47C5-B5C4-CD9D4DE333FBQ35613233-98650C55-120C-4E5D-9F29-82DE5A8DC5A3Q35674158-EADD8385-FCB2-4EA0-9D76-486C9F276ED4Q35796700-FD97DE7C-48DF-4A65-A577-1766EF974CF6Q35799427-F0EEC85B-2CC5-4354-A7F1-EF7DB34B4A14Q35808466-FEEC8732-4AB5-45FA-9A83-181FDBA19B44Q35871726-22B2A1D6-E93D-4C12-AD8C-BE2893AF676DQ35971029-399470E8-52F0-4B8D-9C9E-1C81C346FE64Q36022539-0711C6DC-400B-42EB-BF56-D893242214BCQ36083324-C6585132-C2A4-4AF1-93E8-CEC27B67D10AQ36108119-9276F3F2-2047-45E7-9F24-CB2C12083639Q36118294-BF20DFAE-2A02-486A-B75B-086DBE9986D2Q36131489-83D27630-41EB-4FC9-B52F-805F4B199CB4
P2860
Bispecific T-cell engaging antibodies for cancer therapy
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Bispecific T-cell engaging antibodies for cancer therapy
@ast
Bispecific T-cell engaging antibodies for cancer therapy
@en
Bispecific T-cell engaging antibodies for cancer therapy
@nl
type
label
Bispecific T-cell engaging antibodies for cancer therapy
@ast
Bispecific T-cell engaging antibodies for cancer therapy
@en
Bispecific T-cell engaging antibodies for cancer therapy
@nl
prefLabel
Bispecific T-cell engaging antibodies for cancer therapy
@ast
Bispecific T-cell engaging antibodies for cancer therapy
@en
Bispecific T-cell engaging antibodies for cancer therapy
@nl
P3181
P1433
P1476
Bispecific T-cell engaging antibodies for cancer therapy
@en
P2093
Carsten Reinhardt
Patrick A Baeuerle
P304
P3181
P356
10.1158/0008-5472.CAN-09-0547
P407
P577
2009-06-15T00:00:00Z